Track
:
Track 02: Project/Portfolio Management and Strategic Planning
Program Code:
103
Date:
Monday, June 24, 2013
Time:
11:00 AM to 12:30 PM
EST
Location:
104C
CHAIR
:
Gregg Schneider, (SCHNON), Director, R&D Financial Management, Otsuka Pharmaceutical Development & Commercialization, Inc., United States
Gregg Schneider has been at Otsuka for 15 years managing the US R&D financial plan. As part of a larger global organization, the role involves integrating the US R&D financial plan into the parent company's Japanese P&L, requiring close collaboration with Japanese collegues in Tokyo and Osaka.
SPEAKER
(S):
Vladimir Shnaydman, PhD (SPKNON), President, ORBee Consulting, United States
Vladimir has BS & MS in EE & CS, MS in Applied Mathematics, and Ph.D. in Engineering. He contributed to many industries biotechnology, data storages, water resources, telecommunications. Dr. Shnaydman published more than 50 papers. He is co-author of three books.
Expertise in drug development and project leadership in/out-licensing due diligence, strategic development, fundraising, SME not-for-profit and VC, market access. Head of Translational Sciences at Aptiv Solutions a global consultancy group for drug and device development advice and expertise
Description
This symposium will address adopting an adaptive design strategy at a portfolio level in order to provide significant value to the critical decision-making required to deliver an optimized pipeline of products. We will also look at the substantial challenges faced by generic companies in maximizing the value of their portfolio planning and aligning available and projected resources and strategic goals.